Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology' returned 6 results - Page 1 of 1  FEATURED RESULTS Drug Delivery in Cancer - Technologies, Markets and Companies Cancer Diagnostic Testing World Markets Antibody Drug Target Atlas in Oncology Pediatric Hematology and Oncology: Scientific Principles and... Antibody Drug Target Atlas in Oncology   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies   Bioseeker, Sep 2011, Pages: 4045 : Includes 347 Tables Total Number of Pages: 1,944 Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies Triple Target Atlas in Oncology Drug Development   Bioseeker, Feb 2012 and four major tumor types in detail: Targeted Therapy Strategies in Cancer: Apoptosis Angiogenesis/VDA/VTA Antibodies Immunomodulators & Vaccines Protein Kinase Inhibitors Major Tumor Types: Breast Antibody Drug Targets and Focus on Breast & Prostate Cancer   Bioseeker, Nov 2007, Pages: 380 in Oncology Reported to Act as Protein Kinase Inhibitors Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage Table 73: Antibody Pipeline Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists   La Merie, Sep 2009, Pages: 133 . The clinically validated target provides a low risk opportunity for new technologies with proteins, RNA, antibodies and vaccines for validation of the technologies. Multi-target receptor tyrosine kinase (RTK Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas   Bioseeker, Sep 2007, Pages: 500 care indications - Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer - The included competitive landscape between the five big Cancer Drug Discoveries: what the future holds FULL REPORT   Espicom Business Intelligence Ltd, May 2007, Pages: 652 the processes involved in NSCLC formation several new targeted therapies have evolved which modulate growth factor pathways. Two small-molecular tyrosine kinase inhibitors, Iressa (AstraZeneca) and Tarceva (Roche Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network